Cargando…
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...
Autores principales: | Wiciński, Michał, Górski, Karol, Wódkiewicz, Eryk, Walczak, Maciej, Nowaczewska, Magdalena, Malinowski, Bartosz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177465/ https://www.ncbi.nlm.nih.gov/pubmed/32218354 http://dx.doi.org/10.3390/ijms21072275 |
Ejemplares similares
-
Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury
por: Wiciński, Michał, et al.
Publicado: (2020) -
Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases
por: Wiciński, Michał, et al.
Publicado: (2019) -
Beneficial Effects of Resveratrol Administration—Focus on Potential Biochemical Mechanisms in Cardiovascular Conditions
por: Wiciński, Michał, et al.
Publicado: (2018) -
Liraglutide and its Neuroprotective Properties—Focus on Possible Biochemical Mechanisms in Alzheimer’s Disease and Cerebral Ischemic Events
por: Wiciński, Michał, et al.
Publicado: (2019) -
Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease
por: Wiciński, Michał, et al.
Publicado: (2018)